Alliance Global Partners Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $32
Immunome Inc IMNM
$21.41
▼ -4.16%
($-0.93)
⬇️ Below Yest. Low
🎢 High Beta
Open
$22.43
Prev Close
$22.34
Day Range
$21.15 – $22.65
52W Range
$10.00 – $30.06
Market Cap
$2.43B
Beta
2.67
EPS (TTM)
$-2.51
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-02 |
| Shares Out. | 113,250,000 |
| Website | immunome.com/ ↗ |
| Phone | 16103213700 |
| Employees | 177 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$73.1M |
| Free Cash Flow | -$219.1M |
| Total Assets | $565.4M |
| Total Liabilities | $40.3M |
| Equity | $525.1M |
About Immunome Inc
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Immunome Inc is a publicly traded company under the ticker symbol IMNM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
20 analysts (2026-09-01)